海正藥業(600267.SH)收到問詢函 要求説明前期放棄優先認購權、此次進一步收購少數股權的原因及必要性
格隆匯 7 月 29日丨海正藥業(600267.SH)公佈,2020年7月29日,公司收到上海證券交易所上市公司監管一部下發的《關於對浙江海正藥業股份有限公司發行股份、可轉換公司債券及支付現金購買資產並募集配套資金暨關聯交易預案信息披露的問詢函》。
其中包括,公司擬收購控股子公司瀚暉製藥49%股權,瀚暉製藥系公司與輝瑞於2012年合資設立,持股比例分別為51%和49%,輝瑞於2017年將其持有的49%股權轉讓給其全資子公司HPPC,其後將HPPC100%股權轉讓給第三方Sapphire,公司針對上述股權轉讓表示放棄優先購買權。此次交易中,瀚暉製藥49%股權的預估交易價格為43.37億元至44.84億元,前次Sapphire為購買該等股權向輝瑞支付約2.86億美元。
要求公司補充披露:(1)結合此次交易對上市公司經營、財務的影響,説明在前期放棄優先認購權的情況下,此次進一步收購少數股權的原因及必要性;(2)前後兩次交易估值差異的原因及合理性。請財務顧問發表意見。
另外,預案披露,公司以現金方式支付的交易價格為15億元,應於標的資產過户完成後15個交易日內匯出。截至2020年1季度末,公司賬面貨幣資金23.33億元,短期借款及一年內到期的非流動負債合計75.98億元。
請公司補充披露:(1)本次購買資產是否以募集配套資金到位為前提;(2)如募集資金未能及時到位,説明本次交易支付現金的具體來源以及計劃安排,是否會影響上市公司正常生產經營活動,並提示相關風險等。請財務顧問發表意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.